IRCT138802071852N1已完成未知
Evaluation of effectiveness of H.pylori eradication on regression of gastric precancerous lesions in the first degree relatives of patients with gastric cancer. A long term double blind randomized controlled clinical trial
Digestive Disease Research Center, Tehran University of Medical Sciences0 个研究点目标入组 600 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40 years 至 65 years（—）
- 性别
- All
入选标准
- •First degree relatives of gastric cancer patients, age between 40 and 65 years, presence of diffuse gastritis, positive urease test
- •Exclusion criteria: significant lesions in stomach (ulcer, diffuse gastric erosions or erosive duodenits, gastric neoplasia or severe dysplasia verified by histology), negative Helicobacter Pylori (Negative urease test and no H. Pylori in all specimens by histology)
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Evaluation of the efficasy of H. pylori eradication therapies using different PPI.gastritis caused by H. pylori infectionJPRN-UMIN000014366Hirosaki University Graduate School of Medicine200
已完成
3 期
The effect of quadriple regimen on the eradication rate of Helicobacter pyloriEn Helicobacter pylori.Helicobacter pylori [H.pylori] as the cause of diseases classified to other chaptersB98.0IRCT20080901001155N32Rasht University of Medical Sciences420
招募中
不适用
The efficacy of H. pylori eradication therapy with sitafloxacin-metronidazole-vonaprazan 10 day regimeJPRN-UMIN000022236Keio University School of Medicine100
招募中
不适用
The efficacy of H. pylori eradication therapy with sitafloxacin-metronidazole-vonaprazan regimeHelicobacter pylori infectionJPRN-jRCTs031180412Hirata Kenro100
进行中（未招募）
不适用
Efficacité comparative de l'éradication de H.pylori et d'un inhibiteur de pompe à proton vs. l'abstention thérapeutique sur lésions gastriques induite par l'aspirine à faible dose chez les malades traités au long cours en prévention d'une thrombose coronaire ou vasculaire cérébrale-Aspylori. - ASPYLORIlésions ulcérées gastriques chez les malades traités au long cours par aspirine en prévention d'une thrombose coronaire ou vasculaire cérébrale.EUCTR2007-003827-19-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)